Prohost Biotech - Exclusive Biotech Research - A Comprehensive Resource for Biotech News

Jazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio

March 5, 2025 0

Jazz Pharmaceuticals to Acquire Chimerix Today, March 5, 2025, Jazz Pharmaceuticals (JAZZ) and Chimerix (CMRX) announced the companies …

AstraZeneca and Daiichi Sankyo Enhertu: CHMP Recommends Approval In The EU For Patients With HER2-low or HER2-Ultralow Metastatic Breast Cancer Following At Least One Endocrine Therapy

March 4, 2025 0

AstraZeneca and Daiichi Sankyo AstraZeneca (AZN) and Daiichi Sankyo’s (DSKYF) (trastuzumab deruxtecan) has been recommended for approval …

New Data Advance Sanofi’s Scientific Leadership Across Innovative Treatments for Inflammatory Skin Diseases

March 3, 2025 0

Sanofi New Data Paris, February 28, 2025, Sanofi (SNY) will present 26 abstracts, including one late-breaking presentation …

Can Cassava Sciences Resurrect When Simufilam is Used to Treat Seizures Related to Rare Neurodevelopmental Disorders Instead of Alzheimer’s Disease?

February 28, 2025 0

Cassava Sciences in the NEWS Cassava Sciences, Inc. (SAVA) announced that it entered into an agreement …

Alnylam Pharmaceuticals Press Release Highlights Significant Pipeline Progress and Platform Innovation at R&D Day

February 25, 2025 0

– Showcases multiple potentially transformative near- and mid-stage therapies in ATTR amyloidosis, cardiovascular disease, and Neuroscience, …

Conferences Announced by Verona Pharma and GRAIL Inc

February 24, 2025 0

Verona Pharma Conference Announcements Verona Pharma (VRNA) announces that senior management will present a company overview …

The European Commission Granted Approval to Gilead Sciences’ Seladelpar in Combination with UDCA for the Treatment of Primary Biliary Cholangitis

February 21, 2025 0

Gilead Sciences On February 20, 2025, Gilead Sciences (GILD) announced that the European Commission (EC) granted …

Q & A About Alnylam Pharmaceuticals

February 19, 2025 0

Alnylam Pharmaceuticals Questions & Answers Q: Why has Alnylam Pharmaceuticals’ stock plummeted recently? A: We do …

Soon, Many Treatments for Life-Threatening Diseases Will Become History. Time to Select Biotech Companies With Novel Advanced Technologies and Products

February 18, 2025 0

What About GRAIL Inc? GRAIL Inc (GRAL) is a healthcare company on a mission to detect …

Sanofi Updates on Extraintestinal Pathogenic E. coli Vaccine Phase 3 Clinical Study

February 13, 2025 0

Sanofi A scheduled review of the E.mbrace phase 3 study (clinical trial identifier: NCT04899336) conducted by …

Our Prohost Small Test and Anavex Life Sciences Earning Report

February 12, 2025 0

Anavex Life Sciences Below Today is the earnings report day for Anavex Life Sciences (AVXL) and …

Boehringer Ingelheim Product Nerandomilast Meets Primary Endpoint in Phase III Study in Progressive Pulmonary Fibrosis

February 10, 2025 0

Boehringer Ingelheim Today, Boehringer Ingelheim, a private Company announced that the FIBRONEER™-ILD trial met its primary …

Eledon Pharmaceuticals Announces Use of Tegoprubart as Key Component of Immunosuppression Regimen in its Second Transplant of a Genetically Modified Pig Kidney into a Human

February 7, 2025 0

Eledon Pharmaceuticals The patient was treated in the procedure, conducted at Mass General Transplant Center and …

Supernus Pharmaceuticals Announced FDA Approval of product ONAPGO for the Treatment of Motor Fluctuations in Adults with Advanced Parkinson’s Disease

February 5, 2025 0

Supernus Pharmaceuticals Supernus Pharmaceuticals (SUPN) - a biopharmaceutical company focused on developing products for the treatment …

CHMP Issued Positive Opinion for Subcutaneous RYBREVANT® Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer

February 3, 2025 0

Halozyme Therapeutics Halozyme Therapeutics (HALO) announced that Janssen-Cilag International NV, a Johnson & Johnson company, received …

Vertex Outstanding and Promising News

January 31, 2025 0

Vertex Pharmaceuticals Yesterday, January 30, 2025, Vertex Pharmaceuticals (VRTX) announced FDA approval of journavx™(suzetrigine), a First-in-Class …

The U.S. FDA Approved Daiichi Sankyo and AstraZeneca’s Product ENHERTU® for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following Disease Progression After One or More Endocrine Therapies

January 29, 2025 0

AstraZeneca FDA Approval On January 27, 2025, Daiichi Sankyo (TSE: 4568) and AstraZeneca (AZN) product ENHERTU® (fam-trastuzumab …

Exclusive Market Insight

& Scientific analysis

Latest Articlesddd

Jazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio

AstraZeneca and Daiichi Sankyo Enhertu: CHMP Recommends Approval In The EU For Patients With HER2-low or HER2-Ultralow Metastatic Breast Cancer Following At Least One Endocrine Therapy

New Data Advance Sanofi’s Scientific Leadership Across Innovative Treatments for Inflammatory Skin Diseases

Can Cassava Sciences Resurrect When Simufilam is Used to Treat Seizures Related to Rare Neurodevelopmental Disorders Instead of Alzheimer’s Disease?

Alnylam Pharmaceuticals Press Release Highlights Significant Pipeline Progress and Platform Innovation at R&D Day

Conferences Announced by Verona Pharma and GRAIL Inc

The European Commission Granted Approval to Gilead Sciences’ Seladelpar in Combination with UDCA for the Treatment of Primary Biliary Cholangitis

Q & A About Alnylam Pharmaceuticals

Soon, Many Treatments for Life-Threatening Diseases Will Become History. Time to Select Biotech Companies With Novel Advanced Technologies and Products

Sanofi Updates on Extraintestinal Pathogenic E. coli Vaccine Phase 3 Clinical Study

Our Prohost Small Test and Anavex Life Sciences Earning Report

Boehringer Ingelheim Product Nerandomilast Meets Primary Endpoint in Phase III Study in Progressive Pulmonary Fibrosis

Eledon Pharmaceuticals Announces Use of Tegoprubart as Key Component of Immunosuppression Regimen in its Second Transplant of a Genetically Modified Pig Kidney into a Human

Supernus Pharmaceuticals Announced FDA Approval of product ONAPGO for the Treatment of Motor Fluctuations in Adults with Advanced Parkinson’s Disease

CHMP Issued Positive Opinion for Subcutaneous RYBREVANT® Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer

Vertex Outstanding and Promising News

The U.S. FDA Approved Daiichi Sankyo and AstraZeneca’s Product ENHERTU® for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following Disease Progression After One or More Endocrine Therapies

Complete Preliminary Week 96 Results from Akero Therapeutics EFX Results

Akero Therapeutics Successful Results

Vera Therapeutics Acquires Global Rights to Novel, Next Generation Dual BAFF/APRIL Inhibitor